Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
TEL AVIV, Israel, Feb. 25, 2016 -- Elbit Imaging Ltd. (“EI” or the “Company”) (TASE:EMITF) (NASDAQ:EMITF) announced today, further to the Company’s announcement dated February 1, 2016 regarding the Board of Directors resolution to approve new notes' Buy-Back plan of the Company's series H (“The Notes”) which are traded on the Tel Aviv Stock Exchange ("TASE"), the repurchases of the following Notes was executed since the 1st of February, 2016 to the date herein:
| Note | The acquiring corporation | Quantity purchased (Par value) | Weighted average price | Total amount paid(NIS) |
| Series H | Elbit Imaging Ltd. | 13,741,086 | 88.8 | 12,202,417 |
The entire repurchased notes since the 12th of October, 2015, as the first Notes buyback plan announcement, to the date herein:
| Note | The acquiring corporation | Quantity purchased (Par value) | Weighted average price | Total amount paid(NIS) |
| Series H | Elbit Imaging Ltd. | 69,731,629 | 89.15 | 62,170,416 |
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotels - hotels operation and management. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects.
Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2014, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
For Further Information: Company Contact Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]
